ECG
Everus Construction Group, Inc.
ECG has slightly lower modeled downside risk, despite its lower overall score.
VRT
Vertiv Holdings Co
VRT has the edge over ECG overall, supported by stronger valuation and stronger fundamentals.
ECG Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Healthy | |
| Healthy |
ECG's revenue, profitability, cash flow and balance sheet are all currently healthy.
VRT Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
VRT's revenue, profitability, cash flow and balance sheet are all currently strong.
ECG PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 13x | $87.17 | — |
| Current | 15x | $87.17 | — |
| Cheap | 20x | $113 | +29% |
| Fair | 25x | $142 | +63% |
| Expensive | 31x | $174 | +100% |
Historical ranges are pointers, not guarantees.
ECG's PE is in its cheap range at 15x. If earnings grow as analysts expect, today's price would be 13x next year's earnings.
VRT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 23x | $210 | — |
| Current | 39x | $210 | — |
| Cheap | 58x | $308 | +47% |
| Fair | 72x | $383 | +83% |
| Expensive | 88x | $472 | +125% |
Historical ranges are pointers, not guarantees.
VRT has the edge over ECG in the historical PE scenario, which offers more potential upside but is not a forecast.
ECG Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Improving | |
| Limited | |
| Low |
Analysts expect strong earnings and revenue growth for ECG, with profitability improving. However, they disagree widely on these estimates.
VRT Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Moderate | |
| Moderate |
Analysts expect strong earnings and revenue growth for VRT, with profitability improving.
ECG Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $6.68 | +18% |
| Q3 2026 | $5.66 | +60% |
| Q2 2026 | $4.98 | +53% |
| Q1 2026 | $4.37 | +47% |
| Q4 2025 | $3.95 | +35% |
| Q3 2025 | $3.54 | +37% |
| Q2 2025 | $3.25 | +31% |
| Q1 2025 | $2.98 | +20% |
| Q4 2024 | $2.92 | +19% |
ECG's earnings per share have climbed steadily: $5.66 over the past year, up 60% from the year before, and higher year over year every quarter since late 2024.
VRT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $9.14 | +71% |
| Q3 2026 | $5.35 | +102% |
| Q2 2026 | $4.42 | +111% |
| Q1 2026 | $3.98 | +131% |
| Q4 2025 | $3.41 | +166% |
| Q3 2025 | $2.65 | +75% |
| Q2 2025 | $2.09 | +62% |
| Q1 2025 | $1.72 | +64% |
| Q4 2024 | $1.28 | +7.6% |
VRT has the edge over ECG on earnings, with stronger typical year-over-year growth.
ECG Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.4B | +40% |
| Q2 2026 | $1.2B | +34% |
| Q1 2026 | $1B | +25% |
| Q4 2025 | $1B | +33% |
| Q3 2025 | $986.8M | +30% |
| Q2 2025 | $921.5M | +31% |
| Q1 2025 | $826.6M | +32% |
| Q4 2024 | $759.6M | +19% |
ECG has the edge over VRT on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 8.8% | +1.5 points |
| Q2 2026 | 9.1% | +1.2 points |
| Q1 2026 | 7.5% | +1.3 points |
| Q4 2025 | 6.8% | +0.8 points |
| Q3 2025 | 7.3% | +0.3 points |
| Q2 2025 | 7.9% | +0.6 points |
| Q1 2025 | 6.2% | 0 points |
| Q4 2024 | 6.1% | -2 points |
ECG's operating margin was 8.8% last quarter, up 1.5 points from the same quarter a year ago.
VRT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $4.3B | +61% |
| Q2 2026 | $3.3B | +24% |
| Q1 2026 | $2.6B | +30% |
| Q4 2025 | $2.9B | +23% |
| Q3 2025 | $2.7B | +29% |
| Q2 2025 | $2.6B | +35% |
| Q1 2025 | $2B | +24% |
| Q4 2024 | $2.3B | +26% |
VRT's revenue has grown year over year every quarter since late 2020: $4.3B last quarter, up 61% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 23% | +3.5 points |
| Q2 2026 | 19% | +2.7 points |
| Q1 2026 | 17% | +2.3 points |
| Q4 2025 | 20% | +0.7 points |
| Q3 2025 | 19% | +1.4 points |
| Q2 2025 | 17% | -0.4 points |
| Q1 2025 | 14% | +1.9 points |
| Q4 2024 | 19% | +4.2 points |
VRT has the edge over ECG on profitability, with a higher operating margin.
ECG Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $52.7M | -20% |
| Q2 2026 | $33M | +169% |
| Q1 2026 | $128.2M | +$139.6M |
| Q4 2025 | $23.5M | -65% |
| Q2 2025 | $12.3M | +$37.7M |
| Q1 2025 | -$11.4M | -190% |
| Q4 2024 | $66.9M | -35% |
| Q2 2024 | -$25.4M | -$6M |
ECG generated $237M in free cash flow over the past year, up 78% from the year before.
VRT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $654.9M | +41% |
| Q2 2026 | $926.5M | +233% |
| Q1 2026 | $654.2M | +145% |
| Q4 2025 | $885.6M | +143% |
| Q3 2025 | $463.5M | +36% |
| Q2 2025 | $277.9M | -19% |
| Q1 2025 | $266.8M | +162% |
| Q4 2024 | $364.5M | +18% |
VRT has the edge over ECG on cash flow, with more consistent year-over-year improvement.
ECG Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +19K shares |
| 1 year | +0.2% | +102K shares |
| 3 years | +0.5% | +267K shares |
ECG has the edge over VRT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
VRT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -64.9K shares |
| 1 year | +0.4% | +1.8M shares |
| 3 years | +1.1% | +4.4M shares |
| 5 years | +10% | +36M shares |
| Available history | +63% | +152M shares |
VRT has 393M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | $599.9M |
ECG Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.7x | Very low |
| Q2 2026 | 0.3x | Very low |
| Q1 2026 | -0.1x | Net Cash |
| Q4 2025 | 0.4x | Very low |
| Q3 2025 | 0.5x | Very low |
| Q2 2024 | 1.5x | Healthy |
| Q1 2024 | 0.0x | Very low |
| Q4 2023 | 0.9x | Very low |
ECG's net debt is less than a year of its operating earnings (EBITDA).
VRT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.2x | Net Cash |
| Q2 2026 | 0.1x | Very low |
| Q1 2026 | 0.3x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.8x | Very low |
| Q2 2025 | 0.7x | Very low |
| Q1 2025 | 0.8x | Very low |
| Q4 2024 | 1.0x | Healthy |
VRT has the edge over ECG on leverage, with a lower net debt burden relative to earnings.
ECG Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.4 | Neutral |
| Stochastic | 15.6 | Oversold |
ECG's weekly RSI is 36 (neutral) and its Stochastic is 16 (oversold).
VRT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 26.4 | Neutral |
VRT's weekly RSI is 43 (neutral) and its Stochastic is 26 (neutral).
ECG PE vs Industrials Sector
| Metric | ECG | Sector median | Relative |
|---|---|---|---|
| PE | 15x | 24x | 36% below |
| PE % | 9 | 30 | 21 pts below |
ECG has the edge over VRT on valuation relative to its sector.
VRT PE vs Industrials Sector
| Metric | VRT | Sector median | Relative |
|---|---|---|---|
| PE | 39x | 24x | 63% above |
| PE % | 3 | 58 | 55 pts below |
VRT is trading at 39x earnings, a 63% premium to the Industrials sector's median of 24x.
ECG Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $104.2 | 16% below |
| 20 week MA | $118.5 | 26% below |
| 50 week MA | $119.1 | 27% below |
| 100 week MA | $92.3 | 5.5% below |
VRT has stronger trend alignment. ECG is above 0 of 4 weekly averages versus VRT above 2 of 5.
VRT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $221.8 | 5.5% below |
| 20 week MA | $254.4 | 18% below |
| 50 week MA | $253.9 | 17% below |
| 100 week MA | $189.1 | 11% above |
| 200 week MA | $123.5 | 70% above |
VRT has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 70% above its 200-week average.
ECG Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $52.5 | $69.9 | +33% |
| 2025 | $69.9 | $90.1 | +29% |
| 2026 YTD | $90.1 | $87.2 | -3.2% |
ECG has finished every year since 2024 higher, and it's down 3.2% so far in 2026.
VRT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $10.9 | $18.9 | +73% |
| 2021 | $18.9 | $24.9 | +31% |
| 2022 | $24.9 | $12.8 | -48% |
| 2023 | $12.8 | $48.0 | +275% |
| 2024 | $48.0 | $115.1 | +140% |
| 2025 | $115.1 | $167.6 | +46% |
| 2026 YTD | $167.6 | $209.6 | +25% |
VRT has the edge over ECG on returns for 2026, with the stronger performance.